US WorldMeds acquires Orbus Therapeutics

DifGen Pharmaceuticals completes European Decentralised Procedure for Tafamidis 61 mg Capsules

Astellas and Audax Biosciences sign exclusive option and licence agreement for DAX-044

Lynk Pharmaceuticals reports positive Phase III trial results for zemprocitinib in rheumatoid arthritis

IRLAB Therapeutics receives US patent allowance for Parkinson's drug candidate IRL1117

Thor Medical signs three-year isotope supply agreement with Medicines Discovery Catapult

Enhertu wins EU approval for HER2-positive early breast cancer treatment

Riboscience reports Phase 1a/b overall survival data for ENPP1 inhibitor RBS2418

Cumberland Pharmaceuticals to submit New Drug Application for ifetroban

Innovent Biologics' sintilimab new indication application accepted for review by NMPA

Genmab reports 28.2-month median overall survival with petosemtamab combination in Phase 2 trial

Akeso presents Phase III HARMONi-GI1 trial results in biliary tract cancer at ESMO 2026

Sichuan Kelun-Biotech announces Phase III OptiTROP-Lung04 study results at 2026 ESMO

Zhejiang Wenda Pharma reports positive NHWD-870 HCl oral BET inhibitor Phase II trial results at 2026 ESMO Annual Meeting

Lunit and Summit to apply AI-powered SCOPE IO platform for tumour microenvironment analysis in immuno-oncology development